BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25621798)

  • 1. Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT.
    Takano K; Fuji S; Uchida N; Ogawa H; Ohashi K; Eto T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Fukuda T
    Bone Marrow Transplant; 2015 Apr; 50(4):553-8. PubMed ID: 25621798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
    Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation.
    Ringdén O; Labopin M; Gorin NC; Volin L; Torelli GF; Attal M; Jouet JP; Milpied N; Socié G; Cordonnier C; Michallet M; Atienza AI; Hermine O; Mohty M;
    Br J Haematol; 2012 Apr; 157(2):220-9. PubMed ID: 22299728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
    Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
    Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
    Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic stem cell transplantation in the elderly. Predicting the risk for non relapse mortality.
    Berro M; Basquiera AL; Rivas MM; Foncuberta MC; Burgos R; Jaimovich G; Milovic V; Martínez Rolón J; Remaggi G; Alberbide J; Milone J; Prates V; Rizzi ML; Jarchum G; García JJ; Kusminsky G
    Medicina (B Aires); 2015; 75(4):201-6. PubMed ID: 26339873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.
    Tanaka Y; Kurosawa S; Tajima K; Tanaka T; Ito R; Inoue Y; Okinaka K; Inamoto Y; Fuji S; Kim SW; Tanosaki R; Yamashita T; Fukuda T
    Bone Marrow Transplant; 2016 Apr; 51(4):553-9. PubMed ID: 26752142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
    El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
    Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.
    Penack O; Tridello G; Hoek J; Socié G; Blaise D; Passweg J; Chevallier P; Craddock C; Milpied N; Veelken H; Maertens J; Ljungman P; Cornelissen J; Thiebaut-Bertrand A; Lioure B; Michallet M; Iacobelli S; Nagler A; Mohty M; Cesaro S
    Bone Marrow Transplant; 2016 Mar; 51(3):418-23. PubMed ID: 26501769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.